Orexo AB (publ) (STO:ORX)
17.48
+0.54 (3.19%)
At close: Feb 17, 2025
Orexo AB Revenue
In the year 2024, Orexo AB had annual revenue of 590.00M SEK, down -7.64%. Orexo AB had revenue of 160.30M in the quarter ending December 31, 2024, a decrease of -3.43%.
Revenue
590.00M
Revenue Growth
-7.64%
P/S Ratio
1.00
Revenue / Employee
5.36M
Employees
110
Market Cap
588.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 590.00M | -48.80M | -7.64% |
Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
Dec 31, 2020 | 663.60M | -181.20M | -21.45% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.03B |
Getinge AB | 34.76B |
Sectra AB | 3.14B |
Camurus AB | 1.87B |
Medicover AB | 23.97B |
Vitrolife AB | 3.61B |
Elekta AB | 17.88B |
Vimian Group AB | 4.29B |
Orexo AB News
- 6 weeks ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire
- 2 months ago - Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology - Seeking Alpha
- 2 months ago - Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology - PRNewsWire
- 4 months ago - Orexo initiates new study of OX640 in participants with allergic rhinitis - PRNewsWire
- 4 months ago - Orexo AB reports Q3 results - Seeking Alpha
- 5 months ago - Orexo´s Nomination Committee for the Annual General Meeting 2025 - PRNewsWire
- 6 months ago - Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 - PRNewsWire
- 7 months ago - Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose - PRNewsWire